Association of regulatory T cells with renal outcomes in patients with proliferative lupus nephritis

Abstract

Background

Despite progress in the diagnosis and treatment of proliferative lupus nephritis (PLN), the prognosis remains unfavorable. Previous investigations have suggested that the deficiency of regulatory T cells (Tregs) is involved in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). But the prognostic value of Tregs in PLN remains controversial. This study aimed to investigate the association of Tregs with renal outcomes in patients with PLN.

Methods

The baseline and follow-up data of patients with biopsy-proven PLN were collected in this study. All patients were divided into two groups according to whether the renal endpoint event occurred. Clinicopathologic features and therapeutic responses were compared between the two groups. Cox regression analyses curve fitting and threshold effect analysis were implemented to investigate the relationship between Tregs level and the long-term renal outcomes. The renal endpoint was defined as end-stage kidney disease (ESKD) or doubling the SCr value.

Results

A total of 405 PLN patients were included. After a follow-up of 71.53 (53.13–97.47) months, 42 (10.4%) patients reached the renal endpoint. The Treg cell counts (16/μL) in the renal endpoint group were significantly decreased than that in the non-renal endpoint group (p < 0.001). Univariate and multivariate Cox regression analyses showed that the high level of Tregs was an independent protective factor for the long-term renal prognosis of PLN. Smooth curve fitting of the generalized additive mixed model analysis indicated that the risk of renal endpoint first decreased with Tregs and then slightly increased along with Treg cell levels. The segmented linear model revealed that when Treg cell counts <46/μL, the risk of renal endpoint decreased by 6.8% for every 1 μL increase in Treg levels (p = 0.0029).

Conclusion

Treg cell counts are closely related to the long-term renal outcomes of patients with PLN, and increasing Treg cell levels may play an important role in improving the prognosis of the kidney, but there may be a turning point (i.e., threshold effect) at the Treg cell counts that leads to directional changes in the renal outcomes.

Keywords

Proliferative lupus nephritis regulatory T cells renal outcomes

Get full access to this article

View all access options for this article.

References

Ghodke-Puranik

Niewold

. Immunogenetics of systemic lupus erythematosus: a comprehensive review. J Autoimmun 2015; 64: 125–136.

Bao

Liu

Xie

, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008; 19: 2001–2010.

Zhang

Lee

Liu

, et al. Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney Int 2016; 89: 1337–1345.

Weening

D’Agati

Schwartz

, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241–250.

Ohkura

Kitagawa

Sakaguchi

. Development and maintenance of regulatory T cells. Immunity 2013; 38: 414–423.

Buang

Tapeng

Gray

, et al. Type I interferons affect the metabolic fitness of CD8(+) T cells from patients with systemic lupus erythematosus. Nat Commun 2021; 12: 1980.

Yates

Whittington

Mitchell

, et al. Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis. Clin Exp Immunol 2008; 153: 44–55.

Zhu

Huang

Ming

, et al. Regulatory T-cell levels in systemic lupus erythematosus patients: a meta-analysis. Lupus 2019; 28: 445–454.

Zhang

, et al. The proportion of regulatory T cells in patients with systemic lupus erythematosus: a meta-analysis. J Immunol Res 2018; 2018: 7103219.

10.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

11.

Sharma

Kinsey

. Regulatory T cells in acute and chronic kidney diseases. Am J Physiol Renal Physiol 2018; 314: F679–F698.

12.

Yan

Lee

Jang

, et al. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4(+)CD25(+)Foxp3(+) regulatory T cells. Kidney Int 2017; 91: 603–615.

13.

Raffin

Bluestone

. T(reg) cell-based therapies: challenges and perspectives. Nat Rev Immunol 2020; 20: 158–172.

14.

Ferreira

Muller

Bluestone

, et al. Next-generation regulatory T cell therapy. Nat Rev Drug Discov 2019; 18: 749–769.

15.

Roncarolo

Battaglia

. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7: 585–598.

16.

Jakiela

Kosałka

Plutecka

, et al. Facilitated expansion of Th17 cells in lupus nephritis patients. Clin Exp Immunol 2018; 194: 283–294.

17.

Kopetschke

Klocke

Grießbach

, et al. The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. Arthritis Res Ther 2015; 17: 94.

18.

Żabińska

Krajewska

Kościelska-Kasprzak

, et al. CD4(+)CD25(+)CD127(-) and CD4(+)CD25(+)Foxp3(+) Regulatory T Cell Subsets in Mediating Autoimmune Reactivity in Systemic Lupus Erythematosus Patients. Arch Immunol Ther Exp 2016; 64: 399–407.

19.

Xing

Wang

, et al. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int 2012; 32: 949–958.

20.

Xing

Cui

, et al. Role of Treg cells and TGF-β1 in patients with systemic lupus erythematosus: a possible relation with lupus nephritis. Immunol Invest 2012; 41: 15–27.

21.

Hanaoka

Nishimoto

Okazaki

, et al. A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Res Ther 2020; 22: 88.

22.

Lerkvaleekul

Apiwattanakul

Tangnararatchakit

, et al. Associations of lymphocyte subpopulations with clinical phenotypes and long-term outcomes in juvenile-onset systemic lupus erythematosus. PLoS One 2022; 17: e0263536.

23.

Weigert

von Spee

Undeutsch

, et al. CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. Arthritis Res Ther 2013; 15: R35.

24.

Hanly

O'Keeffe

, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology 2016; 55: 252–262.

25.

Tektonidou

Dasgupta

Ward

. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol 2016; 68: 1432–1441.

26.

Nakagawa

Toyama

Iwata

, et al. The relationship between the modified National Institute of Health activity and chronicity scoring system, and the long-term prognosis for lupus nephritis: a retrospective single-center study. Lupus 2021; 30: 1739–1746.

27.

Zhang

Wang

Zhang

, et al. Association between tubulointerstitial CD8+T cells and renal prognosis in lupus nephritis. Int Immunopharmacol 2021; 99: 107877.

28.

Urrestarazú

Otatti

Silvariño

, et al. Lupus nephritis in males: clinical features, course, and prognostic factors for end-stage renal disease. Kidney Int Rep 2017; 2: 905–912.

29.

Vajgel

Oliveira

Costa

, et al. Initial renal histology and early response predict outcomes of Brazilian lupus nephritis patients. Lupus 2020; 29: 83–91.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.37 MB